Cargando…

Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease

AIM: To evaluate risk factors for primary sclerosing cholangitis (PSC) recurrence (rPSC) after orthotopic liver transplantation (OLT) in patients with well-preserved colons. METHODS: We retrospectively evaluated the medical records of all patients transplanted for PSC in our center between July 1994...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajer, Lukas, Slavcev, Antonij, Macinga, Peter, Sticova, Eva, Brezina, Jan, Roder, Matej, Janousek, Radim, Trunecka, Pavel, Spicak, Julius, Drastich, Pavel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250922/
https://www.ncbi.nlm.nih.gov/pubmed/30487703
http://dx.doi.org/10.3748/wjg.v24.i43.4939
_version_ 1783373008899932160
author Bajer, Lukas
Slavcev, Antonij
Macinga, Peter
Sticova, Eva
Brezina, Jan
Roder, Matej
Janousek, Radim
Trunecka, Pavel
Spicak, Julius
Drastich, Pavel
author_facet Bajer, Lukas
Slavcev, Antonij
Macinga, Peter
Sticova, Eva
Brezina, Jan
Roder, Matej
Janousek, Radim
Trunecka, Pavel
Spicak, Julius
Drastich, Pavel
author_sort Bajer, Lukas
collection PubMed
description AIM: To evaluate risk factors for primary sclerosing cholangitis (PSC) recurrence (rPSC) after orthotopic liver transplantation (OLT) in patients with well-preserved colons. METHODS: We retrospectively evaluated the medical records of all patients transplanted for PSC in our center between July 1994 and May 2015 and selected 47 with follow-up of at least 60 mo for further analysis based on strict inclusion and exclusion criteria. rPSC was confirmed by magnetic resonance or endoscopic retrograde cholangiopancreatography and liver biopsy. All patients were evaluated by protocolary pre-OLT colonoscopy with randomized mucosal biopsies. Colonoscopy was repeated annually after OLT. Both organ donors and recipients were human leukocyte antigen (HLA) typed by serological and/or DNA methods. All input data were thoroughly analyzed employing relevant statistical methods. RESULTS: Altogether, 31 men and 16 women with a median (range) age of 36 (15-68) years at the time of OLT and a median follow-up of 122 (60-249) mo were included. rPSC was confirmed in 21/47 (44.7%) of patients, a median 63 (12-180) mo after transplantation. De novo colitis [rPSC in 11/12, P ≤ 0.05, hazard ratio (HR): 4.02, 95% confidence interval (CI): 1.58-10.98] and history of acute cellular rejection (rPSC in 14/25, P ≤ 0.05; HR: 2.66, 95%CI: 1.03-7.86) showed strong positive associations with rPSC. According to the univariate analysis, overlapping features of autoimmune hepatitis (rPSC in 5/5, P ≤ 0.05) and HLA-DRB1*07 in the donor (rPSC in 10/15, P ≤ 0.05) represent other potential risk factors for rPSC, while the HLA-DRB1*04 (rPSC in 0/6, P ≤ 0.05), HLA-DQB1*03 (rPSC in 1/11, P ≤ 0.05), and HLA-DQB1*07 (rPSC in 0/7, P ≤ 0.05) recipient alleles may have protective roles. CONCLUSION: De novo colitis and acute cellular rejection are clinical conditions significantly predisposed towards recurrence of PSC after liver transplantation.
format Online
Article
Text
id pubmed-6250922
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-62509222018-11-28 Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease Bajer, Lukas Slavcev, Antonij Macinga, Peter Sticova, Eva Brezina, Jan Roder, Matej Janousek, Radim Trunecka, Pavel Spicak, Julius Drastich, Pavel World J Gastroenterol Retrospective Study AIM: To evaluate risk factors for primary sclerosing cholangitis (PSC) recurrence (rPSC) after orthotopic liver transplantation (OLT) in patients with well-preserved colons. METHODS: We retrospectively evaluated the medical records of all patients transplanted for PSC in our center between July 1994 and May 2015 and selected 47 with follow-up of at least 60 mo for further analysis based on strict inclusion and exclusion criteria. rPSC was confirmed by magnetic resonance or endoscopic retrograde cholangiopancreatography and liver biopsy. All patients were evaluated by protocolary pre-OLT colonoscopy with randomized mucosal biopsies. Colonoscopy was repeated annually after OLT. Both organ donors and recipients were human leukocyte antigen (HLA) typed by serological and/or DNA methods. All input data were thoroughly analyzed employing relevant statistical methods. RESULTS: Altogether, 31 men and 16 women with a median (range) age of 36 (15-68) years at the time of OLT and a median follow-up of 122 (60-249) mo were included. rPSC was confirmed in 21/47 (44.7%) of patients, a median 63 (12-180) mo after transplantation. De novo colitis [rPSC in 11/12, P ≤ 0.05, hazard ratio (HR): 4.02, 95% confidence interval (CI): 1.58-10.98] and history of acute cellular rejection (rPSC in 14/25, P ≤ 0.05; HR: 2.66, 95%CI: 1.03-7.86) showed strong positive associations with rPSC. According to the univariate analysis, overlapping features of autoimmune hepatitis (rPSC in 5/5, P ≤ 0.05) and HLA-DRB1*07 in the donor (rPSC in 10/15, P ≤ 0.05) represent other potential risk factors for rPSC, while the HLA-DRB1*04 (rPSC in 0/6, P ≤ 0.05), HLA-DQB1*03 (rPSC in 1/11, P ≤ 0.05), and HLA-DQB1*07 (rPSC in 0/7, P ≤ 0.05) recipient alleles may have protective roles. CONCLUSION: De novo colitis and acute cellular rejection are clinical conditions significantly predisposed towards recurrence of PSC after liver transplantation. Baishideng Publishing Group Inc 2018-11-21 2018-11-21 /pmc/articles/PMC6250922/ /pubmed/30487703 http://dx.doi.org/10.3748/wjg.v24.i43.4939 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Bajer, Lukas
Slavcev, Antonij
Macinga, Peter
Sticova, Eva
Brezina, Jan
Roder, Matej
Janousek, Radim
Trunecka, Pavel
Spicak, Julius
Drastich, Pavel
Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease
title Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease
title_full Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease
title_fullStr Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease
title_full_unstemmed Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease
title_short Risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease
title_sort risk of recurrence of primary sclerosing cholangitis after liver transplantation is associated with de novo inflammatory bowel disease
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250922/
https://www.ncbi.nlm.nih.gov/pubmed/30487703
http://dx.doi.org/10.3748/wjg.v24.i43.4939
work_keys_str_mv AT bajerlukas riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT slavcevantonij riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT macingapeter riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT sticovaeva riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT brezinajan riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT rodermatej riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT janousekradim riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT truneckapavel riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT spicakjulius riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease
AT drastichpavel riskofrecurrenceofprimarysclerosingcholangitisafterlivertransplantationisassociatedwithdenovoinflammatoryboweldisease